Herantis Pharma's Manager's Transactions

In This Article:

Herantis Pharma`s Manager`s Transactions

Herantis Pharma Plc
Company release 30 May 2018 at 9:30 am

Herantis Pharma Oyj - Managers` Transactions

____________________________________________

Person subject to the notification requirement

Name: Antti Vuolanto

Position: Other senior manager

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Reference number: 743700W4CQVYAT3WKK38_20180530090744_4

____________________________________________

Transaction date: 2018-05-29

Venue: FIRST NORTH FINLAND (FNFI)

Instrument type: SHARE

ISIN: FI4000087861

Nature of the transaction: ACQUISITION

Transaction details

(1): Volume: 400 Unit price: 6.1 EUR

Aggregated transactions

(1): Volume: 400 Volume weighted average price: 6.1 EUR

____________________________________________

Transaction date: 2018-05-17

Venue: FIRST NORTH FINLAND (FNFI)

Instrument type: SHARE

ISIN: FI4000087861

Nature of the transaction: ACQUISITION

Transaction details

(1): Volume: 400 Unit price: 6.2 EUR

Aggregated transactions

(1): Volume: 400 Volume weighted average price: 6.2 EUR

____________________________________________

Transaction date: 2018-04-09

Venue: FIRST NORTH FINLAND (FNFI)

Instrument type: SHARE

ISIN: FI4000087861

Nature of the transaction: ACQUISITION

Transaction details

(1): Volume: 300 Unit price: 5.9 EUR

Aggregated transactions

(1): Volume: 300 Volume weighted average price: 5.9 EUR
____________________________________________

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225

Distribution:

Nasdaq Helsinki
Main media
www.herantis.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via GlobeNewswire

HUG#2196071